Amylyx Pharmaceuticals, Inc.
AMLX
$14.05
$0.261.89%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -413.42% | -27.05% | |||
| Gross Profit | 413.42% | 27.05% | |||
| SG&A Expenses | -4.82% | 3.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.60% | -15.94% | |||
| Operating Income | -1.60% | 15.94% | |||
| Income Before Tax | 4.17% | 17.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.03% | 17.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.03% | 17.03% | |||
| EBIT | -1.60% | 15.94% | |||
| EBITDA | -1.64% | 15.94% | |||
| EPS Basic | 18.46% | 20.76% | |||
| Normalized Basic EPS | 4.95% | 20.75% | |||
| EPS Diluted | 18.46% | 20.76% | |||
| Normalized Diluted EPS | 4.95% | 20.75% | |||
| Average Basic Shares Outstanding | 17.69% | 4.71% | |||
| Average Diluted Shares Outstanding | 17.69% | 4.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||